1. Home
  2. OLP vs REPL Comparison

OLP vs REPL Comparison

Compare OLP & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo One Liberty Properties Inc.

OLP

One Liberty Properties Inc.

HOLD

Current Price

$24.42

Market Cap

550.9M

Sector

Real Estate

ML Signal

HOLD

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

HOLD

Current Price

$15.67

Market Cap

454.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OLP
REPL
Founded
1982
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
550.9M
454.6M
IPO Year
1995
2018

Fundamental Metrics

Financial Performance
Metric
OLP
REPL
Price
$24.42
$15.67
Analyst Decision
Strong Buy
Hold
Analyst Count
2
9
Target Price
$26.75
$5.67
AVG Volume (30 Days)
76.0K
7.4M
Earning Date
05-05-2026
05-21-2026
Dividend Yield
7.88%
N/A
EPS Growth
N/A
N/A
EPS
1.00
N/A
Revenue
$82,740,000.00
N/A
Revenue This Year
$11.98
N/A
Revenue Next Year
$3.71
N/A
P/E Ratio
$24.53
N/A
Revenue Growth
1.02
N/A
52 Week Low
$19.62
$1.50
52 Week High
$25.88
$15.71

Technical Indicators

Market Signals
Indicator
OLP
REPL
Relative Strength Index (RSI) 53.58 60.32
Support Level $24.40 $9.01
Resistance Level $25.00 $15.71
Average True Range (ATR) 0.46 1.17
MACD 0.05 0.02
Stochastic Oscillator 97.83 77.95

Price Performance

Historical Comparison
OLP
REPL

About OLP One Liberty Properties Inc.

One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred and two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.

Share on Social Networks: